In their opposition to drug importation legislation, the myriad “non-profit” groups funded by drug companies often cynically invoke the evils of counterfeit drugs. We’ve seen this as recently as this week, when an importation bill triumphantly passed in Florida (Prescription Drug Importation Programs HB19). One such group, the Partnership for Safe Medicines, was called out by PolitiFact for essentially lying that the new state law would “allow” imports from China “without FDA inspection,” tacking on that “too many have already died from counterfeit drugs.”
The Florida drug importation bill builds in so many
regulatory checks that it may in fact make importation from Canada into Florida
safer than our “regular” drug supply chain, but that’s for another post. As it
happens, no one has ever been reported killed by a non-controlled prescription
drug imported from a pharmacy that required a valid prescription.
PolitiFact is right to call out PSM, but I’m sad to report
that, yes, there is a very real counterfeit drug problem in the United States.
But, unlike the fake counterfeit drug facts propagated by groups like PSM to
scare people away from buying lower-cost medicines online, it comes in the form
of illegal fentanyl ingredients used
to make counterfeit prescription narcotics.
(more…)Tagged with: Counterfeit Drugs, opioids, pill presses
Drug Companies Front and Center at PSM Interchange Conference
Two weeks ago I brought you some highlights of the PhRMA-led Partnership for Safe Medicines (PSM) Interchange propaganda show, which was held on September 18th. Look over to the left. See that picture. Those logos of big pharmaceutical companies make it abundantly clear who is pushing the distorted message of PSM about personal drug importation and online pharmacies.
I’m not joking about the word “propaganda” applied to the PSM event. The online Merriam Webster dictionary provides the following definition for that word: “ideas or statements that are often false or exaggerated and that are spread in order to help a cause, a political leader, a government, etc.” In this case, as I see it, the “cause” of PSM is the commercial agenda of the pharmaceutical and U.S. pharmacy industries cynically couched behind terms of patient safety. A central message of PSM is that Americans are risking their lives buying medication online from other countries and that there is no way to do so safely. Those are false and exaggerated messages that are potentially leading lawmakers and regulators to overreact and scare Americans from a potential lifeline of affordable prescription drugs. Evidence shows that this has been PhRMA’s communications strategy for more than a decade. (more…)
Tagged with: Counterfeit Drugs, daniel burke, FDA, Interchnage, laganga, Mississippi AG hood, OCI, Partnership for Safe Medicines, phrma, PSM
For the last six months the WSJ has actively reported on fake Avastin purchased by some medical clinics in the United States. The latest report focuses on the fact that the owner of the foreign wholesaler that shipped the fake Avastin to the U.S. is also the owner of a large international online pharmacy called CanadaDrugs.com. The WSJ reporting makes it clear that the wholesale business is separate from CanadaDrugs.com.
CanadaDrugs.com is a long-standing member of the PharmacyChecker.com Verification Program. It takes orders online filled by licensed pharmacies that require a valid prescription. It does not sell Avastin and the WSJ didn’t report any safety problems associated with its operation.
PharmacyChecker.com’s programs are designed to provide information to consumers seeking safe and affordable medication online for their own use. We recognize that importation by medical clinics does occur and the reason is that drug prices of many drugs are unusually high in the United States. We believe that wholesale drug importation presents unique drug supply and safety challenges that should be addressed but are not related to personal drug importation.
Tagged with: avastin, CanadaDrugs.com, Counterfeit Drugs, personal drug importation, Wall Street Journal